Approved HBV Drugs
Approved HBV Drugs
Most Hepatitis B Patients Who Respond to Tenofovir Show Improved Liver Health at 5 Years
- Details
- Category: HBV Treatment
- Published on Thursday, 27 December 2012 00:00
- Written by Liz Highleyman
Treatment with tenofovir (Viread) remains safe and effective over 5 years, and people who achieve sustained viral load suppression experience improvement in liver histology, including regression of fibrosis and cirrhosis, according to study findings described in the December 7, 2012, advance online edition of The Lancet.
AASLD 2012: Entecavir Shows Good Efficacy for Black and Hispanic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 18 December 2012 00:00
- Written by Liz Highleyman
The nucleoside analog entecavir (Baraclude) worked as well for previously untreated African-American and Hispanic/Latino hepatitis B patients as it did for the majority white and Asian study populations in prior clinical trials, according to a poster presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston.
Entecavir (Baraclude) Label Adds Data on Black Patients and Liver Transplant Recipients with HBV
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 16 October 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration this week approved revised product information for entecavir (Baraclude) for the treatment of chronic hepatitis B virus (HBV) infection, adding new data from studies of African-American patients -- showing no differences in pharmacokinetics or safety -- and of people who received liver transplants. 
Hepatitis B Patients with HBeAg Seroconversion on Treatment May Not Have Durable Response
- Details
- Category: HBV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) who achieve hepatitis B "e" antigen (HBeAg) seroconversion when treated with nucleoside/nucleotide analogs are more likely to experience HBeAg seroreversion and HBV reactivation than those with natural clearance, according to a study described in the November 15, 2012, Journal of Infectious Diseases.
Entecavir Alone Works as Well as Combo for First-time Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Treating chronic hepatitis B with entecavir (Baraclude) alone worked as well as dual therapy using entecavir plus tenofovir (Viread) for patients starting treatment for the first time, according to a study described in the September 2012 issue of Gastroenterology.
More Articles...
- Adefovir-resistant Hepatitis B Virus Can Remain Susceptible to Tenofovir
- Heavy Alcohol Use Impairs Biochemical Response to Entecavir for Chronic Hepatitis B
- Tenofovir Is Safe and Effective for Treating Hepatitis B in Adolescents
- Tenofovir Hepatitis B Label Update Adds Info on Adolescents, Long-term Data for Adults
Web Design and Development by